Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities (2021)

ARS Pharmaceuticals' Preferred Stock Liabilities history spans 1 years, with the latest figure at $54.8 million for Q4 2021.

  • For Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $54.8 million; the TTM value through Dec 2021 reached $54.8 million, changed N/A, while the annual FY2021 figure was $54.8 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2021 was $54.8 million at ARS Pharmaceuticals.
  • Across five years, Preferred Stock Liabilities topped out at $54.8 million in Q4 2021 and bottomed at $54.8 million in Q4 2021.